Can eculizumab be discontinued in aHUS?: Case report and review of the literature

BACKGROUND: The management of atypical hemolytic uremic syndrome (aHUS) has evolved into better control of thrombotic microangiopathy (TMA) and recovery of renal functions since the recent introduction of the terminal complement cascade blocker, eculizumab, into clinical use. Better characterization...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Medicine (Baltimore)
Autors principals: Sahutoglu, Tuncay, Basturk, Taner, Sakaci, Tamer, Koc, Yener, Ahbap, Elbis, Sevinc, Mustafa, Kara, Ekrem, Akgol, Cuneyt, Caglayan, Feyza Bayraktar, Unsal, Abdulkadir, Daha, Mohamed R.
Format: Artigo
Idioma:Inglês
Publicat: Wolters Kluwer Health 2016
Matèries:
5200
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC4979790/
https://ncbi.nlm.nih.gov/pubmed/27495036
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/MD.0000000000004330
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars